ArticleJournal of diabetes investigation2025
Ginsenoside Rg1 inhibits angiogenesis in diabetic retinopathy through the miR-100-3p/FBXW7/c-MYC molecular axis.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effect of Korean red ginseng on deep capillary plexus parameters in diabetic retinopathy: A prospective, randomized, double-blind clinical trial.Journal of ginseng research · 2026Article
- DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells.Journal of bioenergetics and biomembranes · 2026Article
- Multi-omics and experimental validation studies reveal key biomarkers of cellular senescence in diabetic retinopathy.Diabetology & metabolic syndrome · 2025Article
- Targeting microRNAs in diabetic retinopathy: from pathogenic mechanisms to therapeutic potentials.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
AIMS/
introductionGinsenoside Rg1 is an active ingredient found mainly in ginseng that has a variety of pharmacological effects, such as hypoglycemic, antioxidant, and anti-inflammatory effects, and it inhibits vascular formation. In this study, we explored the effect of ginsenoside Rg1 on angiogenesis in diabetic retinopathy (DR) on the basis of its ability to inhibit angiogenesis and the specific molecular mechanism involved. MATERIALS AND
methodsWe induced an in vivo model of diabetes by injection of 55 mg/kg streptozotocin (STZ) into the abdominal cavity of SD rats daily for 3 days. Moreover, human retinal microvascular endothelial cells (HRMECs) were treated with 30 mmol/L glucose for 24 h to construct a high-glucose (HG) cell model in vitro. The expression of related genes and proteins was detected by RT-qPCR and Western blotting. HRMECs and retinal damage were evaluated by CCK-8, scratch, tube formation assays, and HE staining.
resultsIn this study, Rg1 inhibited HG-induced angiogenesis of HRMECs and inhibited STZ-induced vascular leakage and capillary degeneration in vivo, alleviating the progression of DR. Mechanistically, Rg1 upregulated the expression of FBXW7 by inhibiting miR-100-3p, thereby promoting the ubiquitination and degradation of c-MYC, inhibiting HG-induced HRMECs proliferation, migration, invasion, and angiogenesis, and improving the development of DR.
conclusionsOverall, our study demonstrates that ginsenoside Rg1 can inhibit DR angiogenesis via the miR-100-3p/FBXW7/c-MYC molecular axis. These findings provide a novel idea for the treatment of DR and provide an experimental basis for further research on the application of Rg1 in the treatment of DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.